Company Overview and News

 
BOURBON First Half 2018 Results

2018-09-06 globenewswire
"While market conditions remained difficult in the first half of 2018, continued efforts made by our teams to bring costs under control combined with the continuing implementation of our strategic plan, #BOURBONINMOTION, enabled us to maintain our operational performance and prepare ourselves to take advantage of the expected turnaround," stated Gaël Bodénès, Chief Executive Officer of BOURBON Corporation.
GBB

 
BOURBON : Résultats du 1er semestre 2018

2018-09-06 globenewswire
« Sur ce premier semestre 2018, nous évoluons dans un contexte de marché toujours difficile. Toutefois, l'engagement continu des équipes dans la maîtrise de nos coûts combiné à la poursuite de la mise en oeuvre de notre plan stratégique #BOURBONINMOTION, nous a permis de préserver notre performance opérationnelle et de nous préparer pour capter la reprise qui s'annonce », déclare Gaël Bodénès, Directeur Général de BOURBON Corporation.
GBB

 
BOURBON : Nomination de Thierry Hochoa en qualité de Directeur Général Adjoint en charge des Finances et de l'Administration

2018-08-06 globenewswire
Nomination de Thierry Hochoa en qualité de Directeur Général Adjoint en charge des Finances et de l'Administration
GBB FTI.WI FTI

 
BOURBON: Appointment of Thierry Hochoa as Chief Financial Officer

2018-08-06 globenewswire
BOURBON Corporation announces today the appointment of Thierry Hochoa as Chief Financial Officer effective as of August 6th, 2018. He reports directly to Gaël Bodénès, Chief Executive Officer of BOURBON Corporation.
GBB

 
BOURBON : Evolution au sein de la Direction générale

2018-07-11 globenewswire
BOURBON Corporation annonce la démission d'Astrid de Bréon de son mandat social de Directrice Générale Déléguée en charge des finances et de l'administration à compter de ce jour. Depuis son arrivée le 1er Février 2017, Astrid de Bréon a largement contribué à la transformation de BOURBON et à la mise en oeuvre du réaménagement durable de l'endettement financier de l'entreprise. Elle continuera d'exercer ses fonctions de Directrice Générale Adjointe en charge des finances et de l'administration jusqu'à son prochain remplacement à ce poste et son départ de l'entreprise.
GBB

 
BOURBON: Evolution within the general management

2018-07-11 globenewswire
BOURBON Corporation announces the resignation of Astrid de Bréon from her position as Chief Financial Officer effective today. Since her arrival on February 1st, 2017, Astrid de Bréon has largely contributed to BOURBON's transformation and to the sustainable reorganization of the company's financial debt. She will continue to exercice her duties untill her replacement and departure from the company.
GBB

 
BOURBON : Bilan semestriel du contrat de liquidité contracté avec CM CIC Market Solutions

2018-07-04 globenewswire
Au titre du contrat de liquidité confié par la société BOURBON CORPORATION à CM-CIC Market Solutions, à la date du 30 juin 2018 les moyens suivants figuraient au compte de liquidité :
GBB

 
BOURBON: Half-year liquidity contract statement contracted with CM CIC Market Solutions

2018-07-04 globenewswire
Under the liquidity contract signed between BOURBON CORPORATION and CM CIC Market Solutions, the following amounts were shown in the liquidity account on June 30, 2018:
GBB

 
BOURBON : Principales décisions de l'Assemblée Générale Mixte du 30 mai 2018

2018-05-31 globenewswire
L'Assemblée Générale Mixte des actionnaires de BOURBON Corporation SA s'est tenue le 30 mai 2018 à 15 heures au Palais Brongniart - Place de la Bourse - à Paris (75002), sous la présidence de M. Jacques de Chateauvieux.
GBB

 
BOURBON: Main decisions of the Combined General Meeting of May 30, 2018

2018-05-31 globenewswire
The Combined General Shareholders' Meeting of BOURBON Corporation SA was held on May 30, 2018 at 3 pm in Palais Brongniart - Place de la Bourse - Paris, and chaired by Mr. Jacques de Chateauvieux.
GBB

 
BOURBON : Information financière du 1er trimestre 2018

2018-05-03 globenewswire
Le chiffre d'affaires ajusté du 1er trimestre 2018 s'élève à 171 millions d'euros (chiffre d'affaires consolidé de 157,6 millions d'euros), en retrait de 13,2 % par rapport au 4ème trimestre 2017, impacté par la baisse de l'activité dans les services Subsea
GBB

 
BOURBON: 1st Quarter 2018 Financial information

2018-05-03 globenewswire
Adjusted revenue for the 1st quarter 2018 amounted to €171 million (consolidated revenue was €157.6 million), down 13.2% compared to the 4th quarter 2017, impacted by the reduced activity in Subsea Services
GBB

 
BOURBON primé "Shipowner of the Year" pour son programme "Smart Shipping" par GST & Shipping2030

2018-04-27 globenewswire
BOURBON a reçu le prix « Shipowner of the Year » à l'occasion de la conférence GST & Shipping2030 à Copenhague. Ce prix récompense le programme « Smart Shipping » déployé par le groupe et constitue un pilier essentiel du plan d'action stratégique #BOURBONINMOTION visant à accélérer sa transformation et à s'adapter aux nouvelles exigences des clients pétroliers.
GBB BVVBY BVINV BVI

 
BOURBON wins the "Shipowner of the Year" award by GST & Shipping2030 for its "Smart Shipping" program

2018-04-27 globenewswire
BOURBON has been awarded the "Shipowner of the Year" award in the context of the GST & Shipping 2030 conference, which was held at the end of March 2018 in Copenhagen. This award recognizes the "Smart Shipping" program that is being deployed by the group and represents an essential pillar of the #BOURBONINMOTION strategic action plan aimed at accelerating its transformation and adapting to oil & gas clients' new requirements.
GBB BVVBY BVINV BVI

 
BOURBON : Communiqué de mise à disposition Document de Référence / Rapport financier annuel 2017

2018-04-25 globenewswire
Le Document de Référence 2017 a été déposé auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D.18-0384 en date du 25 avril 2018.
GBB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...